John Connolly

Dispatch Bio raises $216 million for solid tumor immunotherapy Solid tumors have challenged CAR-T developers Sean Parker, ARCH launch biotech developing a universal immunotherapy statnews.com/2025/07/23/sea…

We are excited to have Eric J. Dimise, PhD kick off the #SITC #Biotech Strategic Meeting at the @NYSE. Looking forward to developing strategic pathways for novel immunotherapy advancements. Learn more: sitcancer.org/edu/sitc-biote…

A landmark study published in @Nature by @aaronmring et al. has revealed that autoantibodies — immune proteins traditionally associated with autoimmune disease — may profoundly influence how cancer patients respond to immunotherapy. bit.ly/4o4HANS

T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below nature.com/articles/s4158…

Startup Dispatch Bio has ambitious plan, research superstars and $216 million to battle cancer bizjournals.com/sanfrancisco/n…

This is really clever. Marry an oncolytic approach with autologous CAR-T. The cancer-specific virus sets up the @cancer cells with a synthetic antigen and adds a special recipe of chemokines and cytokines to beckon in the T cells, then you unleash the engineered CAR-T on it.…

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy | BioPharma Dive biopharmadive.com/news/disptach-…

Parker Institute, ARCH unveil CAR-T biotech with $216M to crack solid tumors endpoints.news/parker-institu…

This user agreement is absolutely wild. You have to sign away your "knowledge, experience, concepts, ideas, and know-how" that the company "may retain and use". Just remember when something is "free", YOU are the product.

Reminder: Binders are a rapidly depreciating commodity (hooray!). Your novel therapeutic targets and hypotheses have never been more precious. Never give up the latter for the former.

Designed protein domains can selectively target intrinsically disordered regions, potentially generating binders for key proteins in biological function and disease. science.org/doi/10.1126/sc… #NBThighlight

Very happy to share our new review on stem-like cells and their role in CD4 T cell differentiation in @TrendsCellBio cell.com/trends/cell-bi… It was great to tackle this topic with my prior mentor @HaydnKissick. Excited to share our thoughts!

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy: Cancer Cell ⁦@PennMedicine⁩ ⁦@parkerici⁩ cell.com/cancer-cell/fu…

To the 23andMe Community, I am incredibly excited and humbled to share with you that TTAM Research Institute (TTAM), a new non—profit medical research organization that I founded and lead, has completed the acquisition of 23andMe.   I formed TTAM and pursued the acquisition of…

Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery | Nature nature.com/articles/s4158…

A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice | Science Translational Medicine science.org/doi/10.1126/sc…

T cells don’t act alone. The immune system’s response to cancer depends on multicellular “hubs” — coordinated networks of immune and non-immune cells. @PelkaLab (@GladstoneInst) has been awarded the 2025 @aaas Wachtel Award for uncovering these hubs, and revealing why some tumors…

𝐂𝐀𝐑-𝐓 𝐋𝐨𝐠𝐢𝐜-𝐆𝐚𝐭𝐢𝐧𝐠: @ArsenalBio CEO @KDrazan describes the idea of logic-gating, which might allow CAR-T therapies to work in solid tumors when targeting more than one antigen is needed. Full interview: biotechtv.com/post/arsenalbi…

Totally cool to see our branding throughout the house during this interview today. Not bad, @KDrazan.

Join a global exchange of innovation! @sitcancer is collaborating with 12 IO organizations for the WIC Asia-Pacific Conference, July 21–22, 2025, in Singapore! Discover the latest advancements in IO from novel treatments to evolving clinical applications: ow.ly/2axM50W0oHY